Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pulmicort Respules · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pulmicort (budesonide) Respules | DRUG | - |
Inclusion Criteria: \- 1. Clinical benefit from continued treatment with budesonide inhalation suspension was expected in patients with bronchial asthma participating in study SD-004-0765, as judged by the investigator(s) at the completion of that study (Visit 11, Week 24), and the patient's caregi...
Pulmicort Respules is used for asthma. It is an investigational small molecule being developed by AstraZeneca PLC for the treatment of asthma, specifically studied in Japanese children with bronchial asthma. The drug is currently in Phase 3 clinical development.
Pulmicort Respules is developed by AstraZeneca PLC, a company listed on the stock exchange under the ticker AZN. The drug is being studied for the treatment of asthma and is currently in Phase 3 clinical development.
Pulmicort Respules is in Phase 3 clinical development. It is an investigational drug for asthma and has not been approved by regulatory authorities. The Phase 3 trial has been completed, with a total enrollment of 54 participants.
Pulmicort Respules has one completed Phase 3 clinical trial, identified as NCT00232648. The trial, titled 'Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma,' enrolled 54 participants in Japan and was not randomized or double-blinded.
Pulmicort Respules is a budesonide inhalation suspension. The clinical trial for the drug is titled 'Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma,' indicating that budesonide is the active ingredient in Pulmicort Respules.